

ACHILES newsletter

December 2019


Investigator Site File (ISF)

Please remember to keep your ISF up to date with current approved versions of study documents. Do not hesitate to contact us if you have questions regarding how to use the ISF.

Inclusion status:

Switzerland and the Netherlands are currently seeking approval, and we expect these sites to be ready for inclusion early in 2020.

Currently, 57 patients are enrolled.



Research news

[The CASPIAN trial](#) confirmed that PD-L1 inhibitors prolong survival in SCLC. The design was similar to the Impower 133 trial, and showed that first-line durvalumab plus platinum-etoposide significantly improved overall survival in extensive-stage SCLC compared with chemotherapy alone ([Lancet 2019: 394:1929-39](#)), supporting the relevance of the ACHILES trial.

Website

We have established a [website for ACHILES](#), where you can find updated information about the trial, inclusion status and FAQ.

*Best wishes for the holidays
from the ACHILES
study team!*



achiles@stolav.no

